Published January 2025
Below is a list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee. For coverage information regarding these medications, please review the MVP Formularies. For more detailed information regarding pharmacy changes, please review our Provider FastFax Library or review all MVP Health Care Medical Policies.
A list of upcoming formulary changes for Plan Year 2025 is available for review: 2025 Commercial and Marketplace Formulary Changes. Changes will take effect on the member’s pharmacy “Plan Year” start date.
Drugs removed from prior authorization for Commercial, Marketplace, and Self-Funded formularies
| Iwilfin |
| Eohilia |
New Drugs excluded for Commercial, Marketplace, and Self-Funded formularies
| Alvaiz |
| Filsuvez |
| Zymfentra |
| Voydeya |
| Fabhalta |
| Idose |
New generics that recently came to market
| Brand Name | Generic Name |
|---|---|
| Victoza | Liraglutide |
| Radicava | Edaravone |
| Endari | Glutamine powder |
| Corlanor | Ivabradine tablets |
| Lucemyra | Lofexidine tablets |
| Emflaza | Deflazacort |
| Sprycel | Dasatinib |
| Oxtellar | Oxcarbazepine |
Policy Updates
Review other articles in this issue regarding formulary, pharmacy policy, and medical policy updates.